These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25572474)

  • 1. Could PD-L1 prove to be an effective therapeutic target for bladder cancer?
    Hafez N; Petrylak DP
    Immunotherapy; 2015; 7(1):1-2. PubMed ID: 25572474
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan S; Vogelzang NJ
    Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-L1 antibody active in metastatic bladder cancer.
    Brower V
    Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
    [No Abstract]   [Full Text] [Related]  

  • 4. Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.
    Schepisi G; Santoni M; Massari F; Gurioli G; Salvi S; Conteduca V; Montironi R; De Giorgi U
    BioDrugs; 2016 Aug; 30(4):263-73. PubMed ID: 27177757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
    Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
    Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy of invasive cancer of the urinary bladder].
    Kharchenko VP; Kaprin AD; Ivanov SA; Klimenko AA
    Vopr Onkol; 2006; 52(6):659-62. PubMed ID: 17338244
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward improved effectiveness of bladder cancer immunotherapy.
    Kalinski P; Gingrich JR
    Immunotherapy; 2015; 7(10):1039-42. PubMed ID: 26507359
    [No Abstract]   [Full Text] [Related]  

  • 9. Can the success with immunotherapy in metastatic urothelial bladder carcinoma be replicated in the neoadjuvant setting?
    Aoun F; Mjaess G; Nemr E; Albisinni S; Roumeguere T
    Immunotherapy; 2020 Dec; 12(17):1209-1212. PubMed ID: 33115304
    [No Abstract]   [Full Text] [Related]  

  • 10. The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.
    Solinas C; Chanzá NM; Awada A; Scartozzi M
    Cancer Treat Rev; 2017 Feb; 53():138-145. PubMed ID: 28113097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of superficial bladder tumors in a hospital department].
    Prekopp G; Rosdy E
    Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the management of bladder cancer: Introduction.
    Smith AB
    Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.
    Keehn A; Gartrell B; Schoenberg MP
    Future Oncol; 2016 Dec; 12(23):2673-2682. PubMed ID: 27609194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.
    Afonso J; Santos LL; Longatto-Filho A; Baltazar F
    Nat Rev Urol; 2020 Feb; 17(2):77-106. PubMed ID: 31953517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    Ghasemzadeh A; Bivalacqua TJ; Hahn NM; Drake CG
    Clin Cancer Res; 2016 Feb; 22(4):793-801. PubMed ID: 26683632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune function determination in patients with bladder cancer.
    Brosman SA; Fahey JL
    Natl Cancer Inst Monogr; 1978 Dec; (49):321-3. PubMed ID: 311893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.